Einloggen

Thematische Bibliographien / Tumefactive demyelinating lesions / Zeitschriftenartikel

Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Tumefactive demyelinating lesions.

Zeitschriftenartikel zum Thema „Tumefactive demyelinating lesions“

Autor: Grafiati

Veröffentlicht am 7. Juni 2025

Zuletzt aktualisiert am 2. August 2025

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Tumefactive demyelinating lesions" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

Barbosa, Brainner Campos, Edson Marchiori, Caio Leal Leidersnaider, Lara Brandao, and Mauricio Castillo. "Demyelinating lesions behaving like aggressive tumours on advanced MRI techniques." Neuroradiology Journal 32, no. 2 (2019): 103–7. http://dx.doi.org/10.1177/1971400919826394.

Der volle Inhalt der Quelle

Annotation:

Tumefactive demyelinating lesions are a rare disorder in which inflammatory demyelination manifests as solitary or multiple focal brain lesions (greater than 2 cm in size), which can be mistaken for glioma, lymphoma, metastasis and in some cases even brain abscess. The symptomatology of tumefactive demyelinating lesions depends on the white matter area involved and includes quickly progressing neurological deterioration of motor, sensory and visual function, praxis, language and mood impairment, as well as seizures. Recognising the key imaging features in a patient with a prior history of demy

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Brod, Staley A., J. William Lindsey, and Flavia Nelson. "Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments." Multiple Sclerosis Journal - Experimental, Translational and Clinical 5, no. 2 (2019): 205521731985575. http://dx.doi.org/10.1177/2055217319855755.

Der volle Inhalt der Quelle

Annotation:

Objective Large demyelinating lesions with possible mass effect (tumefactive multiple sclerosis or tumefactive demyelination) can be mistaken for tumour-like space-occupying lesions suggesting a malignant outcome. Methods We reviewed our own experience of multiple sclerosis subjects ( n = 28) with tumefactive demyelination to determine the relationship between clinical outcomes and lesion evolution, clinical outcomes and their relationship to different therapies. Patients with central nervous system demyelinating disease were identified from our database over the last 10 years. Results No pati

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Weinshenker, Brian G. "Tumefactive demyelinating lesions: Characteristics of individual lesions, individual patients, or a unique disease entity?" Multiple Sclerosis Journal 21, no. 13 (2015): 1746–47. http://dx.doi.org/10.1177/1352458515603801.

Der volle Inhalt der Quelle

Annotation:

Whether or not recurrent tumefactive demyelinating lesions are a unique form of CNS demyelinating disease or part of the continuum of multiple sclerosis is a question raised by the case report on which this commentary is based. Detailed review and immunopathologic study of biopsy material may not only confirm or refute a diagnosis of demyelinating disease, but potentially uncover unique features that may assist in understanding pathophysiology and nosology of rare cases with recurrent tumefactive demyelination.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Hudon, Mark, Richard Farb, A. P. Mitha, et al. "Tumefactive Demyelinating Lesions." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 34, no. 3 (2007): 362–64. http://dx.doi.org/10.1017/s0317167100006831.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Dagher, A. P., and J. Smirniotopoulos. "Tumefactive demyelinating lesions." Neuroradiology 38, no. 6 (1996): 560–65. http://dx.doi.org/10.1007/s002340050308.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Dagher, A. P., and J. Smirniotopoulos. "Tumefactive demyelinating lesions." Neuroradiology 38, no. 6 (1996): 560–65. http://dx.doi.org/10.1007/bf00626098.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Zafar, Lubna, Obaid Ahmed Siddiqui, Shazia Durdana, and Damera Achyuth Kumar. "Tumefactive demyelination-A Rare Presentation of Multiple Sclerosis." Bangladesh Journal of Medical Science 21, no. 4 (2022): 931–34. http://dx.doi.org/10.3329/bjms.v21i4.60259.

Der volle Inhalt der Quelle

Annotation:

Background: Multiple Sclerosis is an inflammatory demyelinating disease having varied manifestations in terms of clinical featuresand radiological features. Rarely it may present as a large demyelinating lesionwith accompanying edema and mass effect, thereby simulating an intracranial tumor, known as Tumefactive Demyelination. Symptoms are usually related to the pressure of a focal mass lesion. When it manifests in a patient without pre-existing MS, it poses a diagnostic challengeas it may mimic a neoplasm, infarct or abscess. Thus, it is essential to recognize this rare clinical entity for pr

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Kalanie, Hossein, Ali Amini Harandi, Reza Bakhshandehpour, and Daryoosh Heidari. "Multiple Large Tumefactive MS Plaques in a Young Man: A Diagnostic Enigma and Therapeutic Challenge." Case Reports in Radiology 2012 (2012): 1–5. http://dx.doi.org/10.1155/2012/363705.

Der volle Inhalt der Quelle

Annotation:

Tumefactive demyelinating lesion is defined as large solitary demyelinating lesion with imaging characteristics mimicking neoplasm. These atypical features include size more than 2 cm, mass effect, edema, and/or ring enhancement. Distinguishing tumefactive lesions from other etiologies of intracranial space occupying lesions is essential to avoid inadvertent surgical or toxic chemotherapeutic intervention. Symptoms are generally atypical for multiple sclerosis (MS) and usually related to the pressure of a focal mass lesion without a history of MS. The clinical presentation and MRI appearance o

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

QI, WEI, GE JIA, XINSHENG WANG, MAOZHI ZHANG, and ZHENYU MA. "Cerebral tumefactive demyelinating lesions." Oncology Letters 10, no. 3 (2015): 1763–68. http://dx.doi.org/10.3892/ol.2015.3481.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Altintas, A., B. Petek, N. Isik, et al. "Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study." Multiple Sclerosis Journal 18, no. 10 (2012): 1448–53. http://dx.doi.org/10.1177/1352458512438237.

Der volle Inhalt der Quelle

Annotation:

Background: Demyelinating lesions over 20 mm in size, referred to as tumefactive demyelinating lesions, can be misdiagnosed as being either a tumor or an abscess. Although some radiological characteristics can help make a differential diagnosis easier, a cerebral biopsy may still be necessary. Objective: Our objective was to assess the clinical characteristics of tumefactive lesions, with or without a diagnosis of multiple sclerosis (MS), and present follow-up data for 54 patients with tumefactive lesions. Methods: Demographic, clinical, radiological and laboratory data were gathered and treat

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

Foo, See Yun, Nurul Hafidzah Rahim, Aida Widure Mustapha Mohd Mustapha, and Noraini Rose Mohd Zaini. "Magnetic Resonance Imaging (MRI) Features in Diagnosing Tumefactive Demyelinating Lesion." Journal Of Cardiovascular, Neurovascular & Stroke 4, no. 3 (2022): 14–20. http://dx.doi.org/10.32896/cvns.v4n3.14-20.

Der volle Inhalt der Quelle

Annotation:

Background: A demyelinating lesion can present as a space occupying lesion in Magnetic Resonance Imaging (MRI) brain. Lesions that have diameter greater than 2 cm is referred as tumefactive demyelinating lesion. These lesions can mimic a brain tumor, namely glioma or primary central nervous system lymphoma. Case presentation: We present two female patients over 30 years old who presented with limb weakness. Their MRI demonstrated typical appearance of a solitary, incomplete rim enhancing lesion that involved the subcortical white matter with minimal mass effect. Also, the rim of enhancement op

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

Koudriavtseva, Tatiana, Domenico Plantone, Carlo Piantadosi, Serena Ruggieri, and Vincenzo Anelli. "Tumefactive demyelinating lesions and pregnancy." Neurology India 67, no. 6 (2019): 1519. http://dx.doi.org/10.4103/0028-3886.273654.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

Fontes-Villalba, Ariadna A., Heath H. French, and John DE Parratt. "Characterisation of tumefactive demyelinating lesions." Journal of Neurology, Neurosurgery & Psychiatry 88, no. 5 (2017): e1.9-e1. http://dx.doi.org/10.1136/jnnp-2017-316074.14.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

Inshasi, Jihad Said, Pournamy Sarathchandran, Mona Chetan Thakre, Nouf Saeed Al Talai, Reem Al Suwaidi, and Abubaker Al Madani. "Oral Cladribine is Effective in the Treatment of Tumefactive Demyelination in Relapsing Remitting Multiple Sclerosis – A Case Report." Open Neurology Journal 14, no. 1 (2020): 109–14. http://dx.doi.org/10.2174/1874205x02014010109.

Der volle Inhalt der Quelle

Annotation:

This case report describes a 32-year old Emirati patient with tumefactive multiple sclerosis (TMS) treated with a short course of cladribine tablets. The patient presented initially with acute onset of progressive gait unsteadiness, lower limb weakness, associated with numbness of four days duration. Neurological examination of right arms and both legs weakness with sensory level at T10. Contrast-enhanced magnetic resonance imaging (MRI) of the brain showed a large tumefactive demyelination with multiple demyelinating lesions in the brain, consistent with a diagnosis of multiple sclerosis. MRI

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

Siffrin, Volker, Wibke Müller-Forell, Harald von Pein, and Frauke Zipp. "How to treat tumefactive demyelinating disease?" Multiple Sclerosis Journal 20, no. 5 (2013): 631–33. http://dx.doi.org/10.1177/1352458513516891.

Der volle Inhalt der Quelle

Annotation:

Glioma-like inflammatory demyelinating lesions can be found in patients with pre-diagnosed multiple sclerosis, but they have also been described as an isolated disease entity. The initial diagnostic work-up usually includes a biopsy for histopathological analysis. However, even after unambiguous histopathologic classification, tumefactive lesions pose a therapeutic challenge. Until now, there have been no guidelines on how to treat patients with these rare and extreme lesion phenotypes. Here we report a patient with a relapsing unifocal tumefactive demyelinating lesion. The patient initially s

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

Lin, Chi-Ju, Shih-Chieh Lin, Kai-Wei Yu, Wen-Yu Ou Yang, Yi-Chung Lee, and Yi-Chu Liao. "Tumefactive Demyelination Lesions: Report on Three Cases." Acta Neurologica Taiwanica 33, no. 4 (2024): 172–76. https://doi.org/10.4103/ant.33-4_112_0080.

Der volle Inhalt der Quelle

Annotation:

Abstract Purpose: Tumefactive demyelination (TD) lesion and its subtype Balo’s concentric sclerosis (BCS), are rare manifestations of central nervous system demyelinating disease. Because of its rarity, physicians might hesitate in reaching a diagnosis or initiating steroid pulse therapy. This study aims at pinpointing the key neuroimaging features to distinguish TD lesions from surgical conditions, and illustrating the clinical outcomes of patients with TD lesions. Case report: Two of the three patients had solitary TD lesions, one 47-year-old man presenting with newly onset seizure and anoth

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

Hardy, Todd A., W. Oliver Tobin, and Claudia F. Lucchinetti. "Exploring the overlap between multiple sclerosis, tumefactive demyelination and Baló’s concentric sclerosis." Multiple Sclerosis Journal 22, no. 8 (2016): 986–92. http://dx.doi.org/10.1177/1352458516641776.

Der volle Inhalt der Quelle

Annotation:

The availability of magnetic resonance imaging (MRI) has led to increasing recognition that multiple sclerosis (MS), tumefactive demyelination (TD) and Baló’s concentric sclerosis (BCS) share many overlapping features. Baló-like lesions, which exhibit limited features of BCS, may represent an intermediate between BCS and typical MS demyelination. Lesions labeled as tumefactive are typically larger, but otherwise have much in common with conventional MS lesions, and TD and BCS lesions can also overlap. In this article, we explore the similarities between typical MS, TD and BCS cases, and reflec

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

Manouchehri, Navid, Nasim Nehzat, Omid Mirmosayeb, Vahid Shaygannejad, and Mahdi Barzegar. "Tumefactive Brain Lesions in Patients with Neuromyelitis Optica Spectrum Disorder." Caspian Journal of Neurological Sciences 5, no. 2 (2019): 96–100. http://dx.doi.org/10.32598/cjns.5.17.96.

Der volle Inhalt der Quelle

Annotation:

Background: Neuromyelitis Optica Spectrum Disorder (NMOSD) is an autoimmune neurological disorder that is characterized by optic neuritis and longitudinally-extended transverse myelitis lesions in spinal segments. Magnetic Resonance Imaging (MRI) findings are part of the diagnostic process in NMOSD patients, and abnormal lesion patterns may cause deviation from a correct diagnosis. Clinical Presentation and Intervention: A 43-year-old female patient with abrupt cognitive loss, motor dysfunction and tumefactive spread of the demyelinating lesions in her brain presented to the Neurology Clinic o

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

Cereda, CW, C. Zecca, L. Mazzucchelli, et al. "Tumefactive demyelinating lesions during etanercept treatment requiring decompressive hemicraniectomy." Multiple Sclerosis Journal 19, no. 6 (2012): 820–23. http://dx.doi.org/10.1177/1352458512461969.

Der volle Inhalt der Quelle

Annotation:

Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory and immunoregulatory cytokine involved in the pathogenesis of several autoimmune disorders. Etanercept, a TNF-α antagonist (anti-TNF-α) acting as a soluble TNF-α receptor, has been associated with neurological demyelinating disorders. This paper aims to report an unusual case showing tumefactive central nervous system (CNS) inflammatory demyelination in a patient in the course of TNF -α antagonist therapy, requiring decompressive hemicraniectomy. This report is based on magnetic resonance imaging (MRI) findings and histology. A biopsy c

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

Morin, Marie-Paule, Yves Patenaude, Anna B. Sinsky, Brenda Banwell, and Guillaume Sébire. "Solitary Tumefactive Demyelinating Lesions in Children." Journal of Child Neurology 26, no. 8 (2011): 995–99. http://dx.doi.org/10.1177/0883073811401402.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

Algahtani, Hussein, Bader Shirah, and Ali Alassiri. "Tumefactive demyelinating lesions: A comprehensive review." Multiple Sclerosis and Related Disorders 14 (May 2017): 72–79. http://dx.doi.org/10.1016/j.msard.2017.04.003.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

Haritanti, A., A. Lefkopoulos, E. Papadopoulou, et al. "Bilateral Tumefactive Multiple Sclerosis Lesions." Rivista di Neuroradiologia 18, no. 3 (2005): 365–70. http://dx.doi.org/10.1177/197140090501800313.

Der volle Inhalt der Quelle

Annotation:

Tumefactive lesions are a rare form of multiple sclerosis (MS) presentation often provoking a diagnostic dilemma with brain tumour or abscess. We describe two cases of tumefactive demyelinating MS plaques and two different approaches. In the first patient the clinical and laboratory findings were consistent with MS, a diagnosis supported by the rapid response to high-dose steroid treatment. On the contrary, atypical clinical, imaging and laboratory findings in our second patient misled us to a diagnosis of a brain tumour. The diagnosis of MS was made after histopathological examination of the

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

Omerhodžić, Ibrahim, Almir Džurlić, Dino Lisica, et al. "Relapsing Tumefactive Demyelination: A Case Report." Acta Medica Academica 47, no. 2 (2018): 193. http://dx.doi.org/10.5644/ama2006-124.231.

Der volle Inhalt der Quelle

Annotation:

<p><strong>Objective. </strong>We present a case of relapsing tumefactive demyelination in a young female patient, that posed a real diagnostic challenge, with a heterogeneous clinical picture, atypical for multiple sclerosis (MS) presentation, and neuroradiological manifestations with a high suspicion of neoplastic diseases.</p><p><strong>Case Report</strong>. An 18-year old female patient presented to our Neurosurgical Out-patients’ Clinic with symptoms atypical for multiple sclerosis, unremarkable neurological deficit, one tumefactive lesion on MRI,

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

Kang, Yu-jin, Sang-Gon Lee, and Suk-Won Ahn. "A Case of Multiple Sclerosis Presenting with Tumefactive Lesions." Journal of Multiple Sclerosis and Neuroimmunology 14, no. 2 (2023): 125–29. http://dx.doi.org/10.59578/jmsni.14.2.125.

Der volle Inhalt der Quelle

Annotation:

Inflammatory demyelinating diseases including multiple sclerosis (MS) are usually diagnosed based on characteristic clinical and radiological findings. However, some demyelinating diseases have presented with growing large mass-like lesions, and it is difficult to differentiate those demyelinating lesions from brain tumors. We report a case of biopsy-proven MS mimicking brain tumor. This case suggests that inflammatory demyelinating diseases including MS have a wide spectrum and can present with the same radiological features as brain tumors such as lymphoma or high-grade glioma.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

Kang, Yu-jin, Sang-Gon Lee, and Suk-Won Ahn. "A Case of Multiple Sclerosis Presenting with Tumefactive Lesions." Journal of Multiple Sclerosis and Neuroimmunology 14, no. 2 (2023): 125–29. http://dx.doi.org/10.59578/jmsni.2023.14.2.125.

Der volle Inhalt der Quelle

Annotation:

Inflammatory demyelinating diseases including multiple sclerosis (MS) are usually diagnosed based on characteristic clinical and radiological findings. However, some demyelinating diseases have presented with growing large mass-like lesions, and it is difficult to differentiate those demyelinating lesions from brain tumors. We report a case of biopsy-proven MS mimicking brain tumor. This case suggests that inflammatory demyelinating diseases including MS have a wide spectrum and can present with the same radiological features as brain tumors such as lymphoma or high-grade glioma.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

Enzinger, Christian, Siegrid Strasser-Fuchs, Stefan Ropele, Peter Kapeller, Reinhold Kleinert, and Franz Fazekas. "Tumefactive demyelinating lesions: conventional and advanced magnetic resonance imaging." Multiple Sclerosis Journal 11, no. 2 (2005): 135–39. http://dx.doi.org/10.1191/1352458505ms1145oa.

Der volle Inhalt der Quelle

Annotation:

In rare instances, demyelinating disorders present with radiological features that mimic a brain tumour. This often leads to biopsy, which-apart from carrying significant morbidity-frequently turns out as nondiagnostic or dispensable. We therefore set out to assess the contribution of repeated conventional magnetic resonance imaging (MRI), 1H-MR spectroscopy and magnetization transfer imaging in establishing a correct diagnosis of tumefactive demyelinating lesions (TDLs). We studied two females and one male, who presented with TDLs that led to brain biopsy in two cases, for up to three years.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

Radhakrishnan, VV, SruthiS Nair, R. Neelima, et al. "Tumefactive demyelinating lesions: A Clinicopathological correlative study." Indian Journal of Pathology and Microbiology 55, no. 4 (2012): 496. http://dx.doi.org/10.4103/0377-4929.107788.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

Given, Curtis A., B. Scott Stevens, and Charles Lee. "The MRI Appearance of Tumefactive Demyelinating Lesions." American Journal of Roentgenology 182, no. 1 (2004): 195–99. http://dx.doi.org/10.2214/ajr.182.1.1820195.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

TürkoÄlu, Recai, Hans Lassmann, Fügen Vardar Aker, John Tzartos, Socrates Tzartos, and Erdem Tüzün. "Recurrent tumefactive demyelinating lesions: a pathological study." Clinical Neuropathology 36, no. 07 (2017): 195–98. http://dx.doi.org/10.5414/np301005.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

Charoensanti, Sudarat, Sutatip Pongcharoen, and Metha Apiwattanakul. "Pediatric Relapsing Anti-NMDAR Encephalitis Crossing with Tumefactive Demyelinating Lesion." Journal of Pediatric Neurology 17, no. 02 (2018): 077–84. http://dx.doi.org/10.1055/s-0038-1636994.

Der volle Inhalt der Quelle

Annotation:

AbstractAnti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is an autoimmune encephalopathy characterized by neuropsychiatric symptoms, autonomic instability, and abnormal movements. Most children who undergo tumor removal and receive appropriate immunosuppressants have substantial neurological improvement. We report a 14-year-old girl with relapsing anti-NMDAR encephalitis who presented with paroxysmal tingling and weakness of the right lower limb. Despite long-term prophylaxis with immunotherapy (azathioprine), tumefactive demyelinating lesion and multifocal subcortical white matter

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

Ekmekci, Ozgul, and Cenk Eraslan. "Silent Tumefactive Demyelinating Lesions and Radiologically Isolated Syndrome." Case Reports in Neurological Medicine 2018 (November 28, 2018): 1–5. http://dx.doi.org/10.1155/2018/8409247.

Der volle Inhalt der Quelle

Annotation:

Demyelinating lesions larger than 2 cm in diameter, with or without edema, are known as tumefactive demyelinating lesions (TDLs). They constitute a rare inflammatory demyelinating disorder of the central nervous system. TDLs are typically characterized by headaches, cortical symptoms such as aphasia, hemiparesis, hemisensory deficits, seizures, and changes in consciousness. TDLs may occur in patients with or without an established diagnosis of MS or may occur as the initial demyelinating event. They may also be observed during follow-up in patients with MS, neuromyelitis optica, acute dissemin

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

Pérez, Carlos A., Anish Patnaik, Sherwin Oommen, Alissa Redko, and Scott B. Mathis. "Tumefactive Demyelinating Lesions in Children: A Rare Case of Conus Medullaris Involvement and Systematic Review of the Literature." Journal of Child Neurology 35, no. 10 (2020): 690–99. http://dx.doi.org/10.1177/0883073820924147.

Der volle Inhalt der Quelle

Annotation:

Tumefactive demyelinating lesions are an uncommon manifestation of demyelinating disease that mimic primary central nervous system neoplasms and can pose a diagnostic challenge in patients without a pre-existing diagnosis of multiple sclerosis. Although a biopsy may be required to distinguish TDL from neoplasms or infection, certain ancillary and radiographic findings may preclude the need for invasive diagnostic procedures. We describe the case of a 15-year-old boy with a tumefactive demyelinating lesion involving the conus medullaris. An exhaustive systematic literature search of pediatric c

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

Sanghi, Avni, Grace Gombolay, and Tuba Khan. "Anti-myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorder (MOGAD) in a Pediatric Patient with Rare Presentation of a Cerebellar Tumefactive Lesion." Neurology 99, no. 23 Supplement 2 (2022): S17.3—S18. http://dx.doi.org/10.1212/01.wnl.0000903168.54950.6a.

Der volle Inhalt der Quelle

Annotation:

ObjectiveNA.BackgroundAnti-myelin oligodendrocyte glycoprotein (MOG) antibodies have been commonly associated with optic neuritis, myelitis, and acute disseminated encephalomyelitis but rarely with tumefactive lesions, especially in children. We report a young child with MOGAD presenting with a tumefactive cerebellar demyelinating lesion.Design/MethodsA retrospective chart reviewResultsA 3-year-old developmentally appropriate boy with fever for five days prior presented for gait changes and a self-resolved seizure lasting less than 5 minutes. Neurologic examination showed abnormal finger to no

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

Akimoto, Jiro, Tomohiro Suda, Ryo Hashimoto, Hirokazu Fukuhara, and Michihiro Kohno. "Magnetic Resonance Imaging Characteristics of Tumefactive Demyelinating Lesions." Journal of Biomedical Science and Engineering 08, no. 05 (2015): 321–26. http://dx.doi.org/10.4236/jbise.2015.85029.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

Weil, Erika L., and Mohammad Obadah Nakawah. "Recurrent tumefactive demyelinating lesions in an elderly woman." Radiology Case Reports 17, no. 12 (2022): 4570–74. http://dx.doi.org/10.1016/j.radcr.2022.09.008.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

Rovira, Alex. "Tumefactive idiopathic inflammatory demyelinating lesions: a diagnostic challenge." Multiple Sclerosis Journal 20, no. 5 (2013): 634–35. http://dx.doi.org/10.1177/1352458513517282.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

Galus, Weronika, Katarzyna Zawiślak-Fornagiel, and Ewa Krzystanek. "Tumefactive multiple sclerosis – a diagnostic and therapeutic challenge." Aktualności Neurologiczne 22, no. 3 (2023): 141–45. http://dx.doi.org/10.15557/an.2022.0017.

Der volle Inhalt der Quelle

Annotation:

Tumefactive multiple sclerosis with the presence of tumefactive demyelinating lesions (TDL) is an infrequent manifestation of multiple sclerosis. It poses a diagnostic challenge, especially in attempts to differentiate it from a central nervous system neoplasm or other demyelinating disorders, such as neuromyelitis optica spectrum disorder (NMOSD). The article reports a case of a 40-year-old female during chronic steroid therapy administered due to an episode of idiopathic transverse myelitis. The patient developed tumour-like brain lesions in the left hemispheric parietal-occipital region. Th

APA, Harvard, Vancouver, ISO und andere Zitierweisen

38

Aleksandrova, Iliyana, N. Topalov, E. Slavkova, et al. "Atypical imaging in children with multiple sclerosis – case presentation." Bulgarian Neurology 25, no. 1 (2024): 27–33. https://doi.org/10.5281/zenodo.15379692.

Der volle Inhalt der Quelle

Annotation:

Atypical demyelinating lesions in multiple sclerosis (MS) (tumefactive demyelinating lesions, lesions with white matter cavitation, leukodystrophy-like lesions), although rare, pose serious differential diagnostic and therapeutic problems.We present 3 clinical cases of children, one with Balo concentric sclerosis and two with multiple sclerosis (MS), who had atypical magnetic resonance findings during the course of the disease or during the initial clinical manifestation. The first patient presented with an acute hemiparesis and hemihypesthesia with MRI evidence of a rounded tumor-like periven

APA, Harvard, Vancouver, ISO und andere Zitierweisen

39

Czeisler, Barry M. "Emergent Management of Central Nervous System Demyelinating Disorders." CONTINUUM: Lifelong Learning in Neurology 30, no. 3 (2024): 781–817. http://dx.doi.org/10.1212/con.0000000000001436.

Der volle Inhalt der Quelle

Annotation:

ABSTRACT OBJECTIVE This article reviews the various conditions that can present with acute and severe central nervous system demyelination, the broad differential diagnosis of these conditions, the most appropriate diagnostic workup, and the acute treatment regimens to be administered to help achieve the best possible patient outcomes. LATEST DEVELOPMENTS The discovery of anti–aquaporin 4 (AQP4) antibodies and anti–myelin oligodendrocyte glycoprotein (MOG) antibodies in the past two decades has revolutionized our understanding of acute demyelinating disorders, their evaluation, and their manag

APA, Harvard, Vancouver, ISO und andere Zitierweisen

40

Bajagain, Madan, Tatsuki Oyoshi, Tomoko Hanada, et al. "Histopathological variation in the demyelinating sentinel lesion of primary central nervous system lymphoma." Surgical Neurology International 11 (October 15, 2020): 342. http://dx.doi.org/10.25259/sni_531_2020.

Der volle Inhalt der Quelle

Annotation:

Background: Primary central nervous system lymphoma (PCNSL) is one of the least common malignant brain tumors. It is usually diagnosed initially as diffuse large B cell lymphoma (DLBCL). In rare cases, however, a demyelinating lesion referred to as a “sentinel lesion” precedes the actual diagnosis, which usually depicts two distinct patterns of inflammatory cells during histological analysis. This case report describes a unique histological finding and describes the recognized variations in sentinel lesion histopathology. Case Description: A 78-year-old female patient was found to have multipl

APA, Harvard, Vancouver, ISO und andere Zitierweisen

41

Plowman, R. Skipper, and Hemant Varma. "Prognostic factors in Tumefactive demyelinating lesions: A retrospective study." Journal of the Neurological Sciences 428 (September 2021): 117591. http://dx.doi.org/10.1016/j.jns.2021.117591.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

42

Yapici, Zuhal, and Mefkure Eraksoy. "Bilateral Demyelinating Tumefactive Lesions in Three Children With Hemiparesis." Journal of Child Neurology 17, no. 9 (2002): 655–60. http://dx.doi.org/10.1177/088307380201700901.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

43

Al Malik, Yaser M. "Tumefactive demyelinating lesions: A literature review of recent findings." Neurosciences 29, no. 3 (2024): 153–60. http://dx.doi.org/10.17712/nsj.2024.3.20230111.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

44

Rozzanigo, Umberto, Pietro Bontempi, Sabrina Marangoni, Bruno Giometto, and Paolo Farace. "T2 Relaxometry in Tumefactive Demyelinating Lesions: A Case Study." Current Research in MRI 1, no. 3 (2023): 82–84. http://dx.doi.org/10.5152/currresmri.2022.222340.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

45

Silsby, Matthew, Pedro S. Lopez, Judy Spies, et al. "039 Estimating the health and economic burden of investigating tumefactive demyelination compared to conventional multiple sclerosis." Journal of Neurology, Neurosurgery & Psychiatry 90, e7 (2019): A13.3—A14. http://dx.doi.org/10.1136/jnnp-2019-anzan.36.

Der volle Inhalt der Quelle

Annotation:

IntroductionTumefactive demyelinating lesions, defined as demyelinating lesions > 2cm in diameter, occur most commonly in association with multiple sclerosis (MS), and can pose a diagnostic challenge. The aim of this study was to estimate the cost and morbidity associated with the diagnostic investigation of patients with tumefactive demyelination (TD) compared to patients with conventional relapsing-remitting MS.MethodsRetrospective review of patients seen between 2013–2018 in clinics at the Brain and Mind Centre, Sydney; a centre with tertiary referral expertise in MS. Records were search

APA, Harvard, Vancouver, ISO und andere Zitierweisen

46

Ikeda, Kristin M., Donald H. Lee, J. Alexander Fraser, Seyed Mirsattari, and Sarah A. Morrow. "Plasma Exchange in a Patient with Tumefactive, Corticosteroid-Resistant Multiple Sclerosis." International Journal of MS Care 17, no. 5 (2015): 231–35. http://dx.doi.org/10.7224/1537-2073.2014-078.

Der volle Inhalt der Quelle

Annotation:

Tumefactive multiple sclerosis (MS) is an aggressive form of MS that can be difficult to treat with standard therapies. In severe MS relapses, plasma exchange (PLEX) has shown some benefit, but reports of its use in patients with tumefactive MS are limited. This article describes the successful use of PLEX in a patient with tumefactive MS. A 46-year-old right-handed woman with a recent diagnosis of MS presented with drowsiness, dysarthria, horizontal nystagmus, and quadriparesis. Her brain magnetic resonance images demonstrated multiple tumefactive demyelinating lesions in the medulla, bilater

APA, Harvard, Vancouver, ISO und andere Zitierweisen

47

Menascu, S., S. Miron, A. Fatal, and A. Achiron. "PO-0846 Tumefactive Demyelinating Lesions In Juvenile-onset Multiple Sclerosis." Archives of Disease in Childhood 99, Suppl 2 (2014): A529.2—A529. http://dx.doi.org/10.1136/archdischild-2014-307384.1475.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

48

Menascu, S., and S. Miron. "OP68 – 2605: Tumefactive demyelinating lesions in juvenile-onset multiple sclerosis." European Journal of Paediatric Neurology 19 (May 2015): S22. http://dx.doi.org/10.1016/s1090-3798(15)30069-6.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

49

Minagar, A. "Dominant perivenular enhancement of tumefactive demyelinating lesions in multiple sclerosis." Yearbook of Neurology and Neurosurgery 2011 (January 2011): 105–6. http://dx.doi.org/10.1016/j.yneu.2010.12.048.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

50

Ikeguchi, Ryotaro, Yuko Shimizu, Kayoko Abe, et al. "Proton magnetic resonance spectroscopy differentiates tumefactive demyelinating lesions from gliomas." Multiple Sclerosis and Related Disorders 26 (November 2018): 77–84. http://dx.doi.org/10.1016/j.msard.2018.08.025.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!